TY - JOUR
T1 - Surgical strategy for sacral tumor resection
AU - Kim, Kwang Ryeol
AU - Kim, Kyung Hyun
AU - Park, Jeong Yoon
AU - Shin, Dong Ah
AU - Ha, Yoon
AU - Kim, Keung Nyun
AU - Chin, Dong Kyu
AU - Kim, Keun Su
AU - Cho, Yong Eun
AU - Kuh, Sung Uk
N1 - Publisher Copyright:
© Yonsei University College of Medicine 2021.
PY - 2021/1
Y1 - 2021/1
N2 - Purpose: This study aimed to present our experiences with a precise surgical strategy for sacrectomy. Materials and Methods: This study comprised a retrospective review of 16 patients (6 males and 10 females) who underwent sacrectomy from 2011 to 2019. The average age was 42.4 years old, and the mean follow-up period was 40.8 months. Clinical data, including age, sex, history, pathology, radiographs, surgical approaches, onset of recurrence, and prognosis, were analyzed. Results: The main preoperative symptom was non-specific local pain. Nine patients (56%) complained of bladder and bowel symptoms. All patients required spinopelvic reconstruction after sacrectomy. Three patients, one high, one middle, and one hemisacrectomy, underwent spinopelvic reconstruction. The pathology findings of tumors varied (chordoma, n=7; nerve sheath tumor, n=4; giant cell tumor, n=3, etc.). Adjuvant radiotherapy was performed for 5 patients, chemotherapy for three, and combined chemoradiotherapy for another three. Six patients (38%) reported postoperative motor weakness, and newly postoperative bladder and bowel symptoms occurred in 5 patients. Three patients (12%) experienced recurrence and expired. Conclusion: In surgical resection of sacral tumors, the surgical approach depends on the size, location, extension, and pathology of the tumors. The recommended treatment option for sacral tumors is to remove as much of the tumor as possible. The level of root sacrifice is a predicting factor for postoperative neurologic functional impairment and the potential for morbidity. Pre-operative angiography and embolization are recommended to prevent excessive bleeding during surgery. Spinopelvic reconstruction must be considered following a total or high sacrectomy or sacroiliac joint removal.
AB - Purpose: This study aimed to present our experiences with a precise surgical strategy for sacrectomy. Materials and Methods: This study comprised a retrospective review of 16 patients (6 males and 10 females) who underwent sacrectomy from 2011 to 2019. The average age was 42.4 years old, and the mean follow-up period was 40.8 months. Clinical data, including age, sex, history, pathology, radiographs, surgical approaches, onset of recurrence, and prognosis, were analyzed. Results: The main preoperative symptom was non-specific local pain. Nine patients (56%) complained of bladder and bowel symptoms. All patients required spinopelvic reconstruction after sacrectomy. Three patients, one high, one middle, and one hemisacrectomy, underwent spinopelvic reconstruction. The pathology findings of tumors varied (chordoma, n=7; nerve sheath tumor, n=4; giant cell tumor, n=3, etc.). Adjuvant radiotherapy was performed for 5 patients, chemotherapy for three, and combined chemoradiotherapy for another three. Six patients (38%) reported postoperative motor weakness, and newly postoperative bladder and bowel symptoms occurred in 5 patients. Three patients (12%) experienced recurrence and expired. Conclusion: In surgical resection of sacral tumors, the surgical approach depends on the size, location, extension, and pathology of the tumors. The recommended treatment option for sacral tumors is to remove as much of the tumor as possible. The level of root sacrifice is a predicting factor for postoperative neurologic functional impairment and the potential for morbidity. Pre-operative angiography and embolization are recommended to prevent excessive bleeding during surgery. Spinopelvic reconstruction must be considered following a total or high sacrectomy or sacroiliac joint removal.
UR - http://www.scopus.com/inward/record.url?scp=85099182854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099182854&partnerID=8YFLogxK
U2 - 10.3349/ymj.2021.62.1.59
DO - 10.3349/ymj.2021.62.1.59
M3 - Article
C2 - 33381935
AN - SCOPUS:85099182854
SN - 0513-5796
VL - 62
SP - 59
EP - 67
JO - Yonsei medical journal
JF - Yonsei medical journal
IS - 1
ER -